Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS)

Bone Marrow Transplantation volume 55, pages 2052–2055 (2020)Cite this article

Subjects

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Fig. 1: Fluid balance over a 8 days period.
Fig. 2: Clinical course of CRS.

References

  1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432–3.

    CAS  Article  Google Scholar 

  2. Ruella M, Kalos M. Adoptive immunotherapy for cancer. Immunol Rev. 2014;257:14–38.

    Article  Google Scholar 

  3. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–5.

    CAS  Article  Google Scholar 

  4. Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45:e124–31.

    CAS  Article  Google Scholar 

  5. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62.

    CAS  Article  Google Scholar 

  6. Gödel P, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M. Understanding cytokine release syndrome. Intensive Care Med. 2018;44:371–3.

    Article  Google Scholar 

  7. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019;25:625–38.

    CAS  Article  Google Scholar 

  8. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23:943–7.

    CAS  Article  Google Scholar 

  9. Gust J, Hay KA, Hanafi L-A, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells. Cancer Discov. 2017;7:1404–19.

    CAS  Article  Google Scholar 

  10. Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8:958–71.

    CAS  Article  Google Scholar 

  11. Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739–48.

    CAS  Article  Google Scholar 

  12. Acharya UH, Dhawale T, Yun S, Jacobson CA, Chavez JC, Ramos JD, et al. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol. 2019;12:195–205.

    CAS  Article  Google Scholar 

  13. Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133:697–709.

    CAS  Article  Google Scholar 

  14. Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med. 2019;11:1–11.

    Article  Google Scholar 

  15. Kogelmann K, Jarczak D, Scheller M, Drüner M. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care. 2017;21:74.

    Article  Google Scholar 

  16. Frimmel S, Hinz M, Schipper J, Bogdanow S, Mitzner S, Koball S. Cytokine adsorption is a promising tool in the therapy of hemophagocytic lymphohistiocytosis. Int J Artif Organs. 2019. https://doi.org/10.1177/0391398819857444.

  17. Hirayama AV, Turtle CJ. Toxicities of CD19 CAR‐T cell immunotherapy. Am J Hematol. 2019;94:S42–9.

    CAS  Article  Google Scholar 

  18. König C, Röhr AC, Frey OR, Brinkmann A, Roberts JA, Wichmann D, et al. In vitro removal of anti-infective agents by a novel cytokine adsorbent system. Int J Artif Organs. 2019;42:57–64.

    Article  Google Scholar 

  19. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95. Blood. 2016;128:1533.

    CAS  Article  Google Scholar 

  20. Burger R, Guidi M, Calpini V, Lamoth F, Decosterd L, Robatel C, et al. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. J Antimicrob Chemother. 2018;73:3413–22.

    CAS  Article  Google Scholar 

  21. Friesecke S, Stecher S-S, Gross S, Felix SB, Nierhaus A. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs. 2017;20:252–9.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The authors thank the patient and his family, we thank Philip Robinson (Hospices civils deLyon) for his assistance in the preparation and editing of the manuscript; We thank Anaelle Caillet (Nurse, Hospices civils de Lyon) to help us taking care of the patient during his stay in the ICU.

Author information

Affiliations

  1. Medical Intensive Care Unit, Hospices Civils de Lyon, Lyon Sud Teaching hospital, 165, chemin du Grand-Revoyet, 69495, Pierre-Bénite cedex, France

    Florent Wallet, Olivia Vassal, Arnaud Friggeri, Julien Bohe & Bernard Allaouchiche

  2. University of Lyon, Claude Bernard Lyon 1 University, 43, boulevard du 11 novembre 1918, 69100, Villeurbanne, France

    Florent Wallet, Emmanuel Bachy, Olivia Vassal, Arnaud Friggeri, Julien Bohe, Lorna Garnier, Gilles Salles & Bernard Allaouchiche

  3. Department of Hematology, Hospices Civils de Lyon, Lyon Sud Teaching hospital, 165, chemin du Grand-Revoyet, 69495, Pierre-Bénite cedex, France

    Emmanuel Bachy & Gilles Salles

  4. Laboratory of Biology and Immunology, Hospices Civils de Lyon, Lyon Sud Teaching hospital, 165, chemin du Grand-Revoyet, 69495, Pierre-Bénite cedex, France

    Lorna Garnier

Authors
  1. Florent Wallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emmanuel Bachy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olivia Vassal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arnaud Friggeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Julien Bohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lorna Garnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gilles Salles
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bernard Allaouchiche
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

F.W., B.A., G.S., E.B. designed the research; F.W., G.S., E.B., B.A., L.G. analysed the data; F.W., G.S., E.B., B.A. wrote the paper; O.V., J.B., L.G., A.F. reviewed the manuscript and made major contributions to the manuscript.

Corresponding author

Correspondence to Florent Wallet.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wallet, F., Bachy, E., Vassal, O. et al. Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS). Bone Marrow Transplant 55, 2052–2055 (2020). https://doi.org/10.1038/s41409-020-0896-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-020-0896-3

Search

Advanced search

Quick links